

FTIR microspectroscopic analysis: future perspectives

Eleftherios P. Paschalis

Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling
4th Medical Department, Hanusch Hospital, Vienna, Austria

Address for correspondence:

Eleftherios P. Paschalis, Ph.D.

Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling
4th Medical Department, Hanusch Hospital

Heinrich Collin Str. 30, A-1140 Vienna, Austria

Ph. (43) 1 91021 86940

Fax (43) 1 91021 86929

E-mail: eleftherios.paschalis@osteologie.at

Summary

It is widely accepted that bone strength depends on both its structural and material properties. The latter, although important, are difficult to establish until fairly recently. The new generation of infrared microspectroscopic and imaging instruments offers a unique tool in determining the material properties of bone as they allow the study of thin tissue sections and the determination of important parameters such as mineral maturity/crystallinity and collagen cross-links ratio in a spatially resolved manner, thus enabling the correlation with bone turnover. Despite the fact that the utility of such techniques as mass screening tools is currently debated since a biopsy is required, studies employing this technology have advanced our knowledge of the underlying mechanism of bone disease and the course of action of various therapeutic protocols.

KEY WORDS: infrared spectroscopy, bone quality, osteoporosis, bone strength, mineral maturity, collagen cross-links.

Bone

Bone is a composite material, consisting mainly of mineral and collagen. In normal humans, cortical bone constitutes approximately 80% of the human skeletal mass and trabecular bone approximately 20%. Bone surfaces may be undergoing formation or resorption, or they may be inactive. These processes occur throughout life in both cortical and trabecular bone. Bone remodeling is a surface phenomenon and in humans occurs on periosteal, endosteal, Haversian canal, and trabecular surfaces (1, 2). The rate of cortical bone remodeling, which may be as high as 50% per year in the mid-shaft of the femur during the first two years of life, eventually declines to a rate of 2%-5% per year in the elderly. Rates of remodeling in trabecular bone are proportionately higher throughout life and may normally be 5-10 times higher than cortical bone remodeling rates in the adult (1, 2). As is evident, tissue age is variable within the

same human.

Osteoporosis & bone strength

Osteoporosis is an increasing public health problem. Currently osteoporosis is estimated to affect 200,000 people per year worldwide, costing the health care system over \$ 10 billion per year in the US alone (3). Historically osteoporosis has been defined as a disease in which there is "too little bone, but what there is, is normal" (4). Recently, osteoporosis was defined as "a disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk" (5). Despite the major efforts (6) being put into producing new therapies to prevent and reduce the bone loss that leads to osteoporosis, and to limit further loss when osteoporosis is recognized, the factors contributing to the fragility of bone are still being determined.

Loss of bone mass, measured clinically as change in bone mineral density (BMD), is considered an important risk factor for bone fragility. However, BMD is not the sole predictor of whether an individual will experience a fracture (7, 8), and there is considerable overlap in BMD between populations that do and do not develop fractures (9-11). It has been demonstrated that for a given bone mass an individual's risk to fracture increases with age (12). Consistent with these findings, numerous investigators have shown that mechanical variables directly related to fracture risk are either independent or not totally accounted for by bone mass itself (13-18). Epidemiological evidence also shows considerable overlap of bone density values between fracture and non-fracture groups suggesting that low bone quantity alone is an insufficient cause of fragility fractures (9, 19-21). It is becoming evident then, that in addition to BMD, bone quality should also be considered when assessing bone strength and fracture risk. Bone quality is a broad term encompassing a plethora of factors such as geometry and bone mass distribution, trabecular bone microarchitecture, microdamage, remodeling activity, along with genetics, body size, environmental factors, and changes in bone tissue material (mineral maturity / crystallinity, collagen cross-links) properties (10, 11, 22).

Bone mineral

Bone mineral is a poorly crystalline hydroxyapatite $[Ca_5(PO_4)_3OH]$ phase. Ion substitutions are abundant. For example, Na^{+1} , and Mg^{+2} are substituting Ca^{+2} ions, HPO_4^{-2} ions substituting the phosphate ions, Cl^{-1} and F^{-1} substituting OH^{-1} , and CO_3^{-2} substituting for either phosphate or hydroxyl groups. Once mineral is deposited in bone by osteoblasts, it is not a static moiety, but rather a dynamic one. Since it is bathed in aqueous biological fluids, the type and extent of these substitutions changes with time resulting in alterations of the mineral maturity, which is accompanied by changes in mineral crystallite size and /or shape (23, 24).

The contribution of mineral maturity, and crystallite size and shape to bone strength is very apparent in the case of fluoride treated bone (25-29).

In both animal models and in humans it has been reported that osteoporotic bone mineral characteristically consists of crystals which are larger and more perfect than in normal bone (30, 31), smaller and less perfect (32), or that there are no differences (33). Typically in these studies, tissues were homogenized prior to analysis, concealing the effect of spatial variations in mineral properties. Recently, utilizing techniques such as Small Angle X-ray Scattering (SAXS), and quantitative backscattered electron imaging (qBEI), the analysis of bone mineral (poorly crystalline hydroxyapatite) at the microscopic level and the contribution of mineral crystallinity (crystallite size) and maturity (chemical composition) to bone strength is being actively pursued (22, 26-29, 34-49). Based on such studies, models for the importance of mineral crystallite shape and size in determining bone strength have been put forth (50).

Bone collagen & collagen cross-links

The organic matrix of bone consists of collagen and a series of non-collagenous proteins and lipids. Some 85%-90% of the total bone protein consists of collagen fibers (51). Type I collagen, the principal component of the organic matrix of bone, as well as other connective tissues, is a large fibrous protein with a highly repetitive amino acid sequence [Gly (glycine) – X – Y]_n (often X is proline and Y is hydroxyproline) (52-54). This repetitive sequence allows three polypeptide chains (called α chains; type I collagen is composed of two $\alpha 1$ and one $\alpha 2$ chains) to fold into a unique triple-helical structure. It consists of three domains: the –NH₂ terminal nontriple helical, the triple helical, and the –COOH terminal nontriple helical domains. The single uninterrupted triple helical domain represents more than 95% of the molecule.

The most distinct feature of type I collagen in mineralized tissues can be seen in its cross-linking chemistry and molecular packing structure (54). The intermolecular cross-linking provides the fibrillar matrices with various mechanical properties such as tensile strength and viscoelasticity. All the known cross-links of type I collagen are condensation products between the prosthetic groups of juxtaposed specific peptidyl residues of lysine (Lys), hydroxylysine (Hyl), and histidine (His). At present, seven major collagen cross-links have been established as naturally occurring intermolecular cross-links. They are (1) dehydrodihydroxylysinonorleucine (deH-DHLNL), (2) dehydrohydroxylysinonorleucine (deH-HLNL), (3) dehydrohistidinohydroxymerodesmosine (deH-HHMD), (4) pyridinoline (Pyr), (5) deoxypyridinoline (d-Pyr; lysyl analog of Pyr), (6) pyrrole, and (7) histidinohydroxylysinonorleucine (HHL). The first three are NaBH₄-reducible (their reduced forms are referred to as DHLNL, HLNL, and HHMD, respectively) and the rest are non-reducible compounds (54-57).

Altered collagen structure and inferior bone mechanical properties are encountered in the case of osteogenesis imperfecta, in both humans and animal models (35,58-68). The importance of collagen intermolecular cross-links to the mechanical performance of bone is also very apparent in the pyridoxine deficient chick animal model (69-71), as well as in lathyrism (72, 73).

Infrared spectroscopy

Molecular bonds are not stationary, but rather undergo motion such as twisting, bending, stretching, rotation and vibration. When irradiated with infrared radiation, these vibrational motions absorb at specific wavelengths, characteristic of the overall configuration of the atoms, and representative of specific functional groups. Moreover, through detailed analysis of the

absorption wavelengths, information may be deduced on the subtle interactions with the surrounding atoms of a molecule. FTIR spectra provide information on all tissue components. The protein and mineral constituents produce intense, structure sensitive IR modes.

IR spectroscopy has been extensively utilized in the analysis of bone mineral (74-99). Spectroscopic and mathematical analysis of the phosphate band by means of techniques such as deconvolution, second derivative spectroscopy, and curvefitting, spectral regions (underlying peaks) were identified and correlated with the various chemical environments present in biological apatites, enabling the monitoring of the calcium phosphate crystal maturity (ionic substitutions, stoichiometry) (78, 79, 84, 88-95, 97, 99).

The protein Amide I (peptide bond C=O stretch) and Amide II (mixed C-N stretch and N-H in-plane bend) modes near 1650 and 1550 wavenumbers (cm⁻¹), undergo frequency and intensity changes as a result of changes in protein secondary structure. The Amide I band is especially sensitive to secondary structures (100). In such studies, information on protein structures is extracted from broad envelopes consisting of component bands arising from the Amide I modes of various secondary structures by applying a technique of resolution enhancement such as Fourier self-deconvolution, second derivative spectroscopy, and difference FTIR (100-106).

Although detailed information on mineral maturity and protein secondary structure was obtainable utilizing these techniques, homogenized bone tissue and / or proteins in solution had to be used, thus it was not possible to correlate the findings with the metabolic activity of bone surfaces (tissue age).

Infrared microspectroscopy

The coupling of an optical microscope with an infrared spectrometer in the early 1990's offered the unique opportunity of studying thin bone tissues with a spatial resolution of ~ 10 μ m, and to select the anatomical areas to be analyzed based on parallel histologically stained sections thus enabling the correlation of the spectroscopic result with bone surface metabolic activity (tissue age). The pioneering work of Drs Mendelsohn and Boskey (107-109) was later followed and expanded by them and others (38,110-124), resulting in a wealth of new information about the mineral component of bone as a function of cellular activity, tissue age, disease, and therapeutic intervention.

A major breakthrough was the development of spectroscopic parameters that enabled for the first time the monitoring of two of the major collagen cross-links (pyr and deH-DHLN) in thin, histologically stained bone sections, allowing the monitoring of the variation in their spatial distribution as a function of anatomical location, cellular activity, and tissue age (116).

As informative as it may be, FTIR microspectroscopic analysis on instruments equipped with a single infrared detector was a time-consuming proposition as analysis of a single section required 2-3 days. The fairly recently available combination of an infrared focal-plane array (FPA) detector and a FTIR microscope is a powerful one for obtaining spectroscopic images with unprecedented image fidelity (125-128). The advantage of this technique lies in the fact that the spectra acquisition and processing time is shortened at least 1000-fold compared with conventional IR microspectroscopy. Use of a step-scanning FTIR spectrometer with an MCT array detector placed at an image focal plane of an IR microscope enables areas 400x400 μ m² to be collected in less than 3-4 minutes at a spatial resolution of ~6.3 μ m. To date, it has been successfully applied in the analysis of cell cultures, and bones from animal models and

humans (116, 117, 129-144).

Infrared microspectroscopy, bone strength & osteoporosis

Infrared microspectroscopic analysis of bone tissue from animal models and humans at equivalent anatomical locations gave great insight to the role of bone quality in determining bone strength (110, 112, 113, 115, 122, 124, 126, 132-134, 145). It became feasible to conclusively show differences in bone mineral maturity between normal and osteoporotic bone at equivalent anatomical locations (110, 112, 113, 122, 124).

Even more revealing was the analysis of the spatial variation in pyr and deH-DHLNL collagen cross-links in the same bones. It was shown that the ratio between these two major collagen cross-links was very different when osteoporotic and normal bones were compared in the area of trabecular bone with actively bone forming surfaces (141, 143). These data are in excellent agreement with recently published clinical observations that homocysteine blood serum level were elevated in patients with increased fracture risk (146-148). It is interesting to note that these differences were also observed between normal, and bone biopsies obtained from pre-menopausal women sustaining spontaneous fractures while having normal BMD and biochemical markers (143), suggesting that this might be a common factor / cause of fragile bone.

The effect of therapeutic protocols on bone quality has also been investigated (114, 115, 118, 121, 139, 140, 144). During these studies, it was discovered that when fracture risk and BMD were divergent, both mineral maturity and pyr / deH-DHLNL collagen cross-link ratio was correlating with fracture risk rather than BMD (137,144), further emphasizing the contribution of bone quality to its mechanical performance.

Future directions

Since the introduction of the Infrared Microspectroscopic analysis in the early 1990's, the debate rages whether it is a diagnostic tool. Although it provides a plethora of useful outcomes, it is our opinion that it is not well suited to be employed as a mass screening tool for the simple reason that it is an invasive technique as a bone biopsy is required. On the other hand, it is ideally suited for cases of fracturing patients whose "classical" risk indicators such as BMD and biochemical markers are normal (144).

On the other hand, it is a powerful research tool, affording unique insights into the pathophysiology of musculoskeletal diseases such as osteoporosis, osteogenesis imperfecta, Paget's disease, osteomalacia, osteopetrosis, osteosclerosis, etc. Its outcomes complement ones obtained through analyses such as histology, histomorphometry, biochemical markers, blood analysis, and BMD measurements, to provide detailed information on the mechanisms that result in healthy and diseased bone.

It is also a useful technique in deducing the changes in the spatial distribution variation of the mineral crystallite maturity and pyr and deH-DHLNL collagen cross-link ratio induced by various therapeutic protocols (114, 115, 118, 121, 139, 140, 142, 144), therefore it may be used in the future not only for evaluating the various therapeutic protocols but also assist in the design of more targeted ones.

Despite that both bone mineral crystallite maturity and pyr / deH-DHLNL collagen cross-link ratio have been shown to correlate well with bone strength, no calibration curve exists as all the cases reported thus far in the literature involved normal (100%) and diseased / fragile bone (0%). Since both mineral maturity and collagen cross-links do change long after they have been synthesized and deposited by the osteoblast as a

consequence of tissue aging, establishing the threshold in the change in these two outcomes that results in mechanically inferior bone will be important as it will provide the calibration curve upon which bone strength may be predicted (when combined with the outcomes of other analyses), and help us discern between aging and disease.

One of the major advantages of Infrared Microspectroscopy is that it can describe the spatial variation of pyr and deH-DHLNL collagen cross-links in mineralized thin tissue sections. These are only two of the major collagen cross-links and as a result only a partial understanding of the spatial and temporal distribution of collagen properties has been achieved. In the future, spectral and mathematical methods should be combined so as to derive spectroscopic parameters that describe all of the known collagen cross-links, as they are important both in the mineralization initiation cascade of events, and in determining bone strength.

The main outcomes of Infrared Microspectroscopic analysis correlate well with bone strength but are not the sole determinants. Moreover, a review of the literature reveals that the variation in material and structural properties of bone is in the 1-10 μm range. It is necessary then in the future to combine Infrared Microspectroscopic analysis with other techniques capable of analyzing thin bone tissue sections with similar spatial resolution such as quantitative backscatter electron imaging (providing information on the bone mineral density distribution at the mm level) (28, 41-45), small angle x-ray scattering (providing precise information on the mineral crystallite size, shape, and alignment to the collagen fibers) (22, 23, 27, 29, 34-37, 149, 150), and nanoindentation (providing information on the bone mechanical properties at discrete anatomical location with a spatial resolution of $1\ \mu\text{m}$) (151, 152), at carefully selected (based on histology / histomorphometry to include cellular activity as a selection criterion) identical anatomical locations so that the contribution of each outcome to bone strength may be calculated.

In conclusion, Infrared Microspectroscopy has proven to be a powerful tool in the establishment of parameters contributing to bone quality and thus bone strength. Nevertheless, more spectroscopic parameters describing the organic matrix should be derived in the future, and quantitation of these against bone strength should be achieved.

References

1. Bullough P. Atlas of Orthopaedic Pathology. Gower Medical Publishing, New York, 1992.
2. Einhorn TA. The Bone Organ System: Form and Function. In: Marcus R, Feldman D, Kelsey J (eds.) Osteoporosis. Academic Press Inc., New York, 1996.
3. Jensen KS, Mosekilde L. A model of vertebral trabecular bone architecture and its mechanical properties. Bone. 1990;11:417-423.
4. Albright F, Reifenstein EC. The Parathyroid Glands and Metabolic Bone Disease. Williams and Wilkins, Baltimore, MD. 1948:pp. 393.
5. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646-650.
6. Mlodzik H. Osteoporosis: analysis of patenting 1990-1994. Expert Opin Ther Pat. 1995;5:543-545.
7. Boyce TM, Bloebaum RD. Cortical aging differences and fracture implications for the human femoral neck. Bone. 1993;14(5):769-773.
8. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254-9.
9. Cummings SR. Are patients with hip fractures more osteoporotic? Review of the evidence. Am J Med. 1985;78(3):487-94.
10. Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind [editorial; comment]. J Bone Miner Res. 2000;

- 15(6):1001-5.
11. McCreade RB, Goldstein AS. Biomechanics of fracture: Is bone mineral density sufficient to assess risk? *J Bone Miner Res.* 2000; 15(12):2305-2308.
 12. Hui S, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. *J Clin Invest.* 1988;81: 1804-9.
 13. Jepsen KJ, Schaffler MB. Bone mass does not adequately predict variations in bone fragility: a genetic approach. *Trans Orthop Res Soc.* 47th Annual Meeting. 2001:114.
 14. Kanis JA, Melton LJ, Christiansen C, Johnston CJ, Haltaev N. Perspective: The diagnosis of osteoporosis. *J Bone Miner Res.* 1994;9:1137-1142.
 15. Kann P, Graeben S, Beyer J. Age-dependence of bone material quality shown by the measurement of frequency of resonance in the ulna. *Calcif Tissue Int.* 1994;54:96-100.
 16. McCabe F, Zhou LJ, Steele CR, Marcus R. Noninvasive assessment of ulnar bending stiffness in women. *J Bone Miner Res.* 1991;6:53-9.
 17. Mosekilde L, Mosekilde L, Danielsen CC. Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals. *Bone.* 1987;79-85.
 18. Parfitt AM. Bone remodeling and bone loss: understanding the pathophysiology of osteoporosis. *Clin Obs Gynecol.* 1987;30:789-811.
 19. Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, Mascioli SR, Scott JC, Seeley DG, Steiger P et al. Appendicular bone density and age predict hip fracture in women: The study of osteoporotic fractures research group. *JAMA.* 1990;263:665-668.
 20. Ott SM. When bone mass fails to predict bone failure. *Calcif Tiss Int.* 1993;53 (suppl):S7-S13.
 21. Schnitzler CM. Bone quality: a determinant for certain risk factors for bone fragility. *Calcif Tissue Int.* 1993;53:S27-31.
 22. Fratzl P, Gupta HS, Paschalis EP, Roschger P. Structure and mechanical quality of the collagen-mineral composite in bone. *J Mater Chem.* 2004;14:2115-2123.
 23. Gadaleta SJ, Mendelsohn R, Paschalis EP, Camacho NP, Betts F, Boskey AL. Fourier Transform Infrared Spectroscopy of Synthetic and Biological Apatites: A Review. In: *Mad Z (ed.) "Mineral Scale Formation and Inhibition". Plenum Press, New York, 1995; pp. 283-297.*
 24. Gadaleta SJ, Paschalis EP, Betts F, Mendelsohn R, Boskey AL. New Infrared Spectra Structure Correlations in the Amorphous Calcium Phosphate to Hydroxyapatite Conversion. *Calcified Tissue International.* 1996;58:9-16.
 25. Calverley PD, Strause LG. The role of trace minerals in osteoporosis. *J Am Coll Nutr.* 1993;12(4):384-9.
 26. Fratzl P, Roschger P, Eschberger J, Abendroth B, Klaushofer K. Abnormal bone mineralization after fluoride treatment in osteoporosis: a small-angle x-ray-scattering study. *J Bone Miner Res.* 1994;9(10):1541-9.
 27. Fratzl P, Schreiber S, Roschger P, Lafage MH, Rodan G, Klaushofer K. Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small-angle X-ray scattering and backscattered electron imaging study. *J Bone Miner Res.* 1996; 11(2):248-53.
 28. Roschger P, Fratzl P, Klaushofer K, Rodan G. Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs. *Bone.* 1997;20(5):393-7.
 29. Rinnerthaler S, Roschger P, Jakob HF, Nader A, Klaushofer K, Fratzl P. Scanning small angle X-ray scattering analysis of human bone sections. *Calcif Tissue Int.* 1999;64(5):422-9.
 30. LeBlanc AD, Schneider VS, Evans HJ, Engelbretson DA, Krebs JM. Bone mineral loss and recovery after 17 weeks of bed rest. *J Bone Min Res.* 1990;5:843-850.
 31. Rai DV, Behar J. Biophysical characterization of osteoporotic bone. *Envir Res.* 1986;40:68.
 32. Grynpass MD, Holmyard D. Changes in quality of bone mineral on aging and in disease. *SEM.* 1988;2:1045-1051.
 33. Grynpass MD, Katz I, Pritzker KPH. Bone quality and bone quantity in osteoporosis. In: Christiansen C, Johansen JS, Riisi BJ (eds.) *Osteoporosis, I. Osteopress, Copenhagen, 1987;pp 364.*
 34. Fratzl P, Groschner M, Vogl G, Plenk H Jr., Eschberger J, Fratzl-Zelman N, Koller K, Klaushofer K. Mineral crystals in calcified tissues: a comparative study by SAXS. *J Bone Miner Res.* 1992; 7(3):329-34.
 35. Fratzl P, Paris O, Klaushofer K, Landis WJ. Bone mineralization in an osteogenesis imperfecta mouse model studied by small-angle x-ray scattering. *J Clin Invest.* 1996;97(2):396-402.
 36. Fratzl P, Schreiber S, Boyde A. Characterization of bone mineral crystals in horse radius by small-angle X-ray scattering. *Calcif Tissue Int.* 1996;58(5):341-6.
 37. Fratzl P, Schreiber S, Klaushofer K. Bone mineralization as studied by small-angle x-ray scattering. *Connect Tissue Res.* 1996; 34(4):247-54.
 38. Camacho NP, Rinnerthaler S, Paschalis EP, Mendelsohn R, Boskey AL, Fratzl P. Complementary information on bone ultrastructure from scanning small angle X-ray scattering and Fourier-transform infrared microspectroscopy. *Bone.* 1999;25(3):287-93.
 39. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. *J Clin Endocrinol Metab.* 2003;88(3):1150-6.
 40. Misof BM, Roschger P, Tesch W, Baldock PA, Valenta A, Messmer P, Eisman JA, Boskey AL, Gardiner EM, Fratzl P, Klaushofer K. Targeted Overexpression of Vitamin D Receptor in Osteoblasts Increases Calcium Concentration Without Affecting Structural Properties of Bone Mineral Crystals. *Calcif Tissue Int.* 2003;6:6.
 41. Roschger P, Fratzl P, Eschberger J, Klaushofer K. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. *Bone.* 1998;23(4):319-23.
 42. Roschger P, Grabner BM, Rinnerthaler S, Tesch W, Kneissel M, Berzlanovich A, Klaushofer K, Fratzl P. Structural development of the mineralized tissue in the human L4 vertebral body. *J Struct Biol.* 2001;136(2):126-36.
 43. Roschger P, Gupta HS, Berzlanovich A, Ittner G, Dempster DW, Fratzl P, Cosman F, Parisien M, Lindsay R, Nieves JW, Klaushofer K. Constant mineralization density distribution in cancellous human bone. *Bone.* 2003;32(3):316-23.
 44. Roschger P, Plenk H Jr., Klaushofer K, Eschberger J. A new scanning electron microscopy approach to the quantification of bone mineral distribution: backscattered electron image grey-levels correlated to calcium K alpha-line intensities. *Scanning Microsc.* 1995;9(1):75-86; discussion 86-8.
 45. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. *Bone.* 2001;29(2):185-91.
 46. Zizak I, Roschger P, Paris O, Misof BM, Berzlanovich A, Bernstorff S, Amenitsch H, Klaushofer K, Fratzl P. Characteristics of mineral particles in the human bone/cartilage interface. *J Struct Biol.* 2003;141(3):208-17.
 47. Jager I, Fratzl P. Mineralized collagen fibrils: a mechanical model with a staggered arrangement of mineral particles. *Biophys J.* 2000;79(4):1737-46.
 48. Tesch W, Vandenbos T, Roschger P, Fratzl-Zelman N, Klaushofer K, Beertsen W, Fratzl P. Orientation of mineral crystallites and mineral density during skeletal development in mice deficient in tissue nonspecific alkaline phosphatase. *J Bone Miner Res.* 2003; 18(1):117-25.
 49. Paris O, Zizak I, Lichtenegger H, Roschger P, Klaushofer K, Fratzl P. Analysis of the hierarchical structure of biological tissues by scanning X-ray scattering using a micro-beam. *Cell Mol Biol (Noisy-le-grand)* 2000;46(5):993-1004.
 50. Gao H, Ji B, Jager IL, Arzt E, Fratzl P. Materials become insensitive to flaws at nanoscale: lessons from nature. *Proc Natl Acad Sci USA.* 2003;100(10):5597-600.

51. Termine JD, Robey PG. Bone Matrix Proteins and the Mineralization Process. In: Favus MJ (ed.) *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, 3rd Edition, An Official Publication of the American Society for Bone and Mineral Research. Lippincott-Raven Publishers, 1996.
52. Prockop DJ, Kivirikko KI. Heritable diseases of collagen. *N Engl J Med*. 1984;311:376-396.
53. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. [Review]. *Annual Review of Biochemistry*. 1995;64:403-434.
54. Yamauchi M. Collagen: The major matrix molecule in mineralized tissues. In: Anderson JJB, Garner SC (eds.) *Calcium and Phosphorus in Health and Disease*. CRC Press, New York, 1996:pp. 127-141.
55. Hansen DA, Eyre DR. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. *J Biol Chem*. 1996;271:26508-26516.
56. Kuypers R, Tyler M, Kurth LB, Jenkins ID, Hogan DJ. Identification of the loci of the collagen-associated Ehrlich Chromogen in Type I collagen confirms its role as a trivalent cross-link. *Biochem J*. 1992;283:129-136.
57. Knott L, Tarlton JF, Bailey AJ. Chemistry of collagen cross-linking: biochemical changes in collagen during the partial mineralization of turkey leg tendon. *Biochem J*. 1997;322(Pt 2):535-42.
58. Phillips CL, Bradley DA, Schlotzhauer CL, Bergfeld M, Liberos-Minotta C, Gawenis LR, Morris JS, Clarke LL, Hillman LS. Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density. *Bone*. 2000;27(2):219-26.
59. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. *Bone*. 2000;26(6):581-9.
60. Jepsen KJ, Schaffler MB, Kuhn JL, Goulet RW, Bonadio J, Goldstein SA. Type I collagen mutation alters the strength and fatigue behavior of Mov13 cortical tissue. *J Biomech*. 1997;30(11-12):1141-5.
61. Misof K, Landis WJ, Klaushofer K, Fratzl P. Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress. *J Clin Invest*. 1997;100(1):40-5.
62. Cassella JP, Pereira R, Prockop DJ, An SY. Mineral changes in a transgenic mouse model for osteogenesis imperfecta. *B J Biomed Sci*. 1993;53(2):100-11.
63. Termine RF, Hume EL, Halfon KW, Prockop DJ. Bone fragility in transgenic mice expressing a partially deleted gene for type I procollagen (COL1A1) parallels the age-dependent phenotype of human osteogenesis imperfecta. *J Bone Miner Res*. 1995;10(12):1837-43.
64. Markolf HJ, Gannon FH, Fallon MD, Mennuti MT, Lodato RF, Kaplan FS. Skeletal dysplasia in perinatal lethal osteogenesis imperfecta. A complex disorder of endochondral and intramembranous ossification. *Clin Orthop*. 1993;(293):327-37.
65. Pereira R, Khillan JS, Helminen HJ, Hume EL, Prockop DJ. Transgenic mice expressing a partially deleted gene for type I procollagen (COL1A1). A breeding line with a phenotype of spontaneous fractures and decreased bone collagen and mineral. *J Clin Invest*. 1993;91(2):709-16.
66. Alman B, Frasca P. Fracture failure mechanisms in patients with osteogenesis imperfecta. *J Orthop Res*. 1987;5(1):139-43.
67. Oxlund H. Relationships between the biomechanical properties, composition and molecular structure of connective tissues. *Connect Tissue Res*. 1986;15(1-2):65-72.
68. Grabner B, Landis WJ, Roschger P, Rinnerthaler S, Peterlik H, Klaushofer K, Fratzl P. Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim). *Bone*. 2001;29(5):453-7.
69. Masse PG, Colombo VE, Gerber F, Howell DS, Weiser H. Morphological abnormalities in vitamin B6 deficient tarsometatarsal chick cartilage. *Scanning Microsc*. 1990;4:667-674.
70. Masse PG, Boskey AL, Pritzker KPH, Mendes M, Weiser H. Vitamin B6 deficiency experimentally-induced bone and joint disorder: microscopic, radiographic and biochemical evidence. *BR J Nutr*. 1994;71:919-932.
71. Masse PG, Rinnac CM, Yamauchi M, Coburn PS, Rucker BR, Howell SD, Boskey AL. Pyridoxine deficiency affects biomechanical properties of chick tibial bone. *Bone*. 1996;18:567-574.
72. Spengler DM, Baylink DJ, Rosenquist JB. Effect of beta-aminopropionitrile on bone mechanical properties. *J Bone Joint Surg. [Am]* 1977;59(5):670-2.
73. Oxlund H, Barckman M, Ortoft G, Andreassen TT. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. *Bone*. 1995;17(4 Suppl):365S-371S.
74. Termine JD, Posner AS. Infrared analysis of rat bone: age dependency of amorphous and crystalline mineral fractions. *Science*. 1966;153(743):1523-5.
75. Termine JD, Posner AS. Infrared absorption of carbonate apatite. *Science*. 1967;155(762):607-8.
76. Wuthier RE. Lipids of mineralizing epiphyseal tissues in the bovine fetus. *J Lipid Res*. 1968;9(1):68-78.
77. Posner AS. Bone mineral on the molecular level. *Fed Proc* 1973; 32(9):1933-7.
78. Termine JD, Lundy DR. Hydroxide and carbonate in rat bone mineral and its synthetic analogues. *Calcif Tissue Res*. 1973;13(1):73-82.
79. Blumenthal NC, Betts F, Posner AS. Effect of carbonate and biological macromolecules on formation and properties of hydroxyapatite. *Calcif Tissue Res*. 1975;18(2):81-90.
80. Baud CA, Bang S, Very JM. Minor elements in bone mineral and their effects on its solubility. *J Biol Buccale*. 1977;5(3):195-202.
81. Cohen L, Kitzes R. Infrared spectroscopy and magnesium content of bone mineral in osteoporotic women. *Isr J Med Sci*. 1981; 7(12):1123-5.
82. Myers HM, Tochon-Danguy HJ, Baud CA. IR absorption spectrophotometric analysis of the complex formed by tetraacycline and synthetic hydroxyapatite. *Calcif Tissue Int*. 1983;35(6):745-9.
83. Nelson DG, McLean J. High-resolution electron microscopy of octacalcium phosphate and its hydrolysis products. *Calcif Tissue Int*. 1984;36(2):219-32.
84. Rai LV, Behari J. Biophysical characterization of osteoporotic bone. *Environ Res*. 1986;40(1):68-83.
85. Legros R, Balmain N, Bonel G. Age-related changes in mineral of rat and bovine cortical bone. *Calcif Tissue Int*. 1987;41(3):137-44.
86. Baud CA, Very JM, Courvoisier B. Biophysical study of bone mineral in biopsies of osteoporotic patients before and after long-term treatment with fluoride. *Bone*. 1988;9(6):361-5.
87. Sauer GR, Wuthier RE. Fourier transform infrared characterization of mineral phases formed during induction of mineralization by collagenase-released matrix vesicles in vitro. *J Biol Chem*. 1988;263(27):13718-24.
88. Rey C, Collins B, Goehl T, Dickson IR, Glimcher MJ. The carbonate environment in bone mineral: a resolution-enhanced Fourier Transform Infrared Spectroscopy Study. *Calcif Tissue Int*. 1989; 45(3):157-64.
89. Rey C, Lian J, Grynaps M, Shapiro F, Zylberberg L, Glimcher MJ. Non-apatitic environments in bone mineral: FT-IR detection, biological properties and changes in several disease states. *Connect Tissue Res*. 1989;21(1-4):267-73.
90. Rey C, Shimizu M, Collins B, Glimcher MJ. Resolution-enhanced Fourier transform infrared spectroscopy study of the environment of phosphate ions in the early deposits of a solid phase of calcium-phosphate in bone and enamel, and their evolution with age. I: Investigations in the epsilon 4 PO4 domain. *Calcif Tissue Int*. 1990; 46(6):384-94.
91. Walters MA, Leung YC, Blumenthal NC, LeGeros RZ, Konsker KA. A Raman and infrared spectroscopic investigation of biological hydroxyapatite. *J Inorg Biochem*. 1990;39(3):193-200.
92. Rey C, Beshah K, Griffin R, Glimcher MJ. Structural studies of the mineral phase of calcifying cartilage. *J Bone Miner Res*. 1991;6(5):515-25.
93. Rey C, Renugopalakrishnan V, Collins B, Glimcher MJ. Fourier transform infrared spectroscopic study of the carbonate ions in bone mineral during aging. *Calcif Tissue Int*. 1991;49(4):251-8.
94. Rey C, Shimizu M, Collins B, Glimcher MJ. Resolution-enhanced Fourier transform infrared spectroscopy study of the environment of

- phosphate ion in the early deposits of a solid phase of calcium phosphate in bone and enamel and their evolution with age: 2. Investigations in the nu3PO4 domain. *Calcif Tissue Int.* 1991;49 (6):383-8.
95. Grynblas MD, Rey C. The effect of fluoride treatment on bone mineral crystals in the rat. *Bone.* 1992;13(6):423-9.
 96. LeGeros RZ, Kijkowska R, Bautista C, LeGeros JP. Synergistic effects of magnesium and carbonate on properties of biological and synthetic apatites. *Connect Tissue Res.* 1995;33(1-3):203-9.
 97. Rey C, Miquel JL, Facchini L, Legrand AP, Glimcher MJ. Hydroxyl groups in bone mineral. *Bone.* 1995;16(5):583-6.
 98. Weiss P, Lapkowski M, Legeros RZ, Bouler JM, Jean A, Daculsi G. Fourier-transform infrared spectroscopy study of an organic-mineral composite for bone and dental substitute materials. *J Mater Sci Mater Med.* 1997;8(10):621-9.
 99. Bohic S, Heymann D, Pouezat JA, Gauthier O, Daculsi G. Transmission FT-IR microspectroscopy of mineral phases in calcified tissues. *C R Acad Sci III.* 1998;321(10):865-76.
 100. George A, Veis A. FTIRS in H₂O Demonstrates that collagen monomers undergo a conformational transition prior to thermal self-assembly in vitro. *Biochemistry* 1991;30(9):2372-2377.
 101. Kennedy DF, Crisma M, Toniolo C, Chapman D. Studies of peptides forming 3(10)- and alpha-helices and beta-bend ribbon structures in organic solution and in model biomembranes by Fourier transform infrared spectroscopy. *Biochemistry.* 1991;30:6541-6548.
 102. Weis MA, Wilkin DJ, Kim HJ, Wilcox WR, Lachman RS, Rimoin DL, Cohn DH, Eyre DR. Structurally abnormal type II collagen in a severe form of Kniest dysplasia caused by an exon 24 skipping mutation. *J Biol Chem.* 1998;273(8):4761-8.
 103. Dong A, Huang P, Caughey WS. Protein secondary structures in water from second-derivative amide I infrared spectra. *Biochemistry.* 1990;29:3303-3308.
 104. Lazarev YA, Grishkovsky BA, Khromova TB. Amide I band spectrum and structure of collagen and related polypeptides. *Biopolymers.* 1985;24:1449-1478.
 105. Lazarev YA, Grishkovsky BA, Khromova TB, Lazareva AV, Grechishko VS. Bound water in the collagen-like triple-helical structure. *Biopolymers.* 1992;32:183-195.
 106. Lazarev YA, Lazareva AV. Infrared spectra and structure of synthetic polypeptides. *Biopolymer.* 1973;17:1107-1214.
 107. Mendelsohn R, Hassankhani F, DiCarlo E, Boskey A. FT-IR microscopy of endochondral ossification at 20 micrometers spatial resolution [published erratum appears in *Calcif Tissue Int.* 1989 Jul; 45(1):2]. *Calcif Tissue Int.* 1989;44(1):20-4.
 108. Boskey AL, Camacho NP, Mendelsohn R, Doty SB, Binderman I. FTIR microscopic mappings of early mineralization in chick limb bud mesenchymal cell cultures. *Calcif Tissue Int.* 1992;51(6):443-8.
 109. Boskey AL, Pleshko N, Doty SB, Mendelsohn R. Applications of Fourier Transform Infrared (FT-IR) Microscopy to the study of Mineralization in Bone and Cartilage. *Cells and Materials.* 1992;2(3):209-220.
 110. Paschalis EP, DiCarlo E, Betts F, Sherman P, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of human osteonal bone. *Calcif Tissue Int.* 1996;59(6):480-7.
 111. Paschalis EP, Jacenko O, Olsen B, Mendelsohn R, Boskey AL. Fourier transform infrared microspectroscopic analysis identifies alterations in mineral properties in bones from mice transgenic for type X collagen. *Bone.* 1996;19(2):151-6.
 112. Paschalis EP, Betts F, DiCarlo E, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of human iliac crest biopsies from untreated osteoporotic bone. *Calcif Tissue Int.* 1997;61(6):487-92.
 113. Paschalis EP, Betts F, DiCarlo E, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of normal human cortical and trabecular bone. *Calcif Tissue Int.* 1997;61(6):480-6.
 114. Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs: effects on bone morphometry and mineral properties. *J Bone Miner Res.* 1999;14(10):1768-78.
 115. Gadeleta SJ, Boskey AL, Paschalis E, Carlson C, Menschik F, Baldini T, Peterson M, Rinnac CM. A physical, chemical, and mechanical study of lumbar vertebrae from normal, ovariectomized, and nandrolone decanoate-treated cynomolgus monkeys (*Macaca fascicularis*). *Bone.* 2000;27(4):541-50.
 116. Paschalis EP, Verdelis K, Doty SB, Boskey AL, Mendelsohn R, Yamauchi M. Spectroscopic characterization of collagen cross-links in bone. *J Bone Miner Res.* 2001;16(10):1821-8.
 117. Aparicio S, Doty SB, Camacho NP, Paschalis EP, Spevak L, Mendelsohn R, Boskey AL. Optimal methods for processing mineralized tissues for Fourier transform infrared microspectroscopy. *Calcif Tissue Int.* 2002;70(5):422-9.
 118. Burr DB, Miller L, Grynblas M, Li J, Boyde A, Mashiba T, Hirano T, Johnston CC. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. *Bone* 2003;33(6):960-9.
 119. Dumas P, Jamin N, Teillaud JL, Miller LM, Beccard B. Imaging capabilities of synchrotron infrared microspectroscopy. *Faraday Discuss.* 2004;126:289-302; discussion 303-11.
 120. Federman S, Miller LM, Sagi I. Following matrix metalloproteinase activity near the cell boundary by infrared micro-spectroscopy. *Matrix Biol.* 2002;21(7):567-77.
 121. Huang RY, Miller LM, Carlson CS, Chance MR. Characterization of bone mineral composition in the proximal tibia of cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment. *Bone.* 2002;30(3):492-7.
 122. Huang RY, Miller LM, Carlson CS, Chance MR. In situ chemistry of osteoporosis revealed by synchrotron infrared microspectroscopy. *Bone.* 2003;33(4):514-21.
 123. Miller LM, Carlson CS, Carr GL, Chance MR. A method for examining the chemical basis for bone disease: synchrotron infrared microspectroscopy. *Cell Mol Biol (Noisy-le-grand).* 1998;44(1):117-27.
 124. Miller LM, Varlamourthy V, Chance MR, Mendelsohn R, Paschalis EP, Betts F, Boskey AL. In situ analysis of mineral content and crystallinity in bone using infrared micro-spectroscopy of the nu(4) PO(4)(3-) vibration. *Biochim Biophys Acta.* 2001;1527(1-2):11-9.
 125. Marcott C, Reeder RC, Paschalis EP, Tatakis DN, Boskey AL, Mendelsohn R. FT-IR Chemical Imaging of Biomineralized Tissues Using a Mercury-Cadmium-Telluride Focal-Plane Detector. *Cellular and Molecular Biology.* 1998;44(1):109-115.
 126. Marcott C, Reeder RC, Paschalis EP, Tatakis DN, Boskey AL, Mendelsohn R. Infrared microspectroscopic imaging of biomineralized tissues using a mercury-cadmium-telluride focal-plane array detector. *Cell Mol Biol (Noisy-le-grand).* 1998;44(1):109-15.
 127. Mendelsohn R, Paschalis EP, Boskey AL. Infrared Spectroscopy, Microscopy, and Microscopic Imaging of Mineralizing Tissues. *Spectra-Structure Correlations from Human Iliac Crest Biopsies.* *J Biomed Optics.* 1999;4(1):14-21.
 128. Mendelsohn R, Paschalis EP, Sherman PJ, Boskey AL. IR Microscopic Imaging of Pathological States and Fracture Healing of Bone. *Applied Spectroscopy.* 2000;54:1183-1191.
 129. Halvorsen YD, Franklin D, Bond AL, Hitt DC, Auchter C, Boskey AL, Paschalis EP, Wilkison WO, Gimble JM. Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cells. *Tissue Eng.* 2001;7(6):729-41.
 130. Khan M, Yamauchi M, Srisawasdi S, Stiner D, Doty S, Paschalis EP, Boskey AL. Homocysteine decreases chondrocyte-mediated matrix mineralization in differentiating chick limb-bud mesenchymal cell micro-mass cultures. *Bone.* 2001;28(4):387-98.
 131. Ou-Yang H, Paschalis EP, Mayo WE, Boskey AL, Mendelsohn R. Infrared microscopic imaging of bone: spatial distribution of CO3(2-). *J Bone Miner Res.* 2001;16(5):893-900.
 132. Atti E, Gomez S, Wahl SM, Mendelsohn R, Paschalis E, Boskey AL. Effects of transforming growth factor-beta deficiency on bone development: a Fourier transform-infrared imaging analysis. *Bone.* 2002;31(6):675-84.
 133. Boskey AL, Paschalis EP, Binderman I, Doty SB. BMP-6 accelerates both chondrogenesis and mineral maturation in differentiating

- chick limb-bud mesenchymal cell cultures. *J Cell Biochem.* 2002; 84(3):509-19.
134. Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. *Calcif Tissue Int.* 2002;71(2):145-54.
135. Boyan BD, Bonewald LF, Paschalis EP, Lohmann CH, Rosser J, Cochran DL, Dean DD, Schwartz Z, Boskey AL. Osteoblast-mediated mineral deposition in culture is dependent on surface microtopography. *Calcif Tissue Int.* 2002;71(6):519-29.
136. Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. *J Bone Miner Res.* 2002;17(2):192-9.
137. Blank RD, Baldini TH, Kaufman M, Bailey S, Gupta R, Yerushov Y, Boskey AL, Coppersmith SN, Demant P, Paschalis EP. Spectroscopically determined collagen Pyr/deH-DHLNL cross-link ratio and crystallinity indices differ markedly in recombinant congenic mice with divergent calculated bone tissue strength. *Connect Tissue Res.* 2003;44(3-4):134-42.
138. Mochida Y, Duarte WR, Tanzawa H, Paschalis EP, Yamauchi M. Decorin modulates matrix mineralization in vitro. *Biochem Biophys Res Commun.* 2003;305(1):6-9.
139. Paschalis EP, Boskey AL, Kassem M, Eriksen EF. Effect of hormone replacement therapy on bone quality in early postmenopausal women. *J Bone Miner Res.* 2003;18(6):955-9.
140. Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL. Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH(1-34) for 18 months. *J Bone Miner Res.* 2003;18(4):769-75.
141. Paschalis EP, Recker R, DiCarlo E, Doty SB, Atti E, Boskey AL. Distribution of collagen cross-links in normal human trabecular bone. *J Bone Miner Res.* 2003;18(11):1942-6.
142. Ouyang H, Sherman PJ, Paschalis EP, Boskey AL, Mendelsohn R. Fourier transform infrared microscopic imaging: effects of estrogen and estrogen deficiency on fracture healing in rat femurs. *Appl Spectrosc.* 2004;58(1):1-9.
143. Paschalis EP, Shane E, Lyritis G, Skarantavos G, Mendelsohn R, Boskey AL. Bone fragility and collagen cross-links. *J Bone Miner Res.* 2004;19(12):2000-4.
144. Paschalis EP, Glass EV, Donley DW, Eriksen EF. Bone Mineral And Collagen Quality In Iliac Crest Biopsies Of Patients Given Teriparatide: New Results From The Fracture Prevention Trial. *J Clin Endocrinol Metab.* 2005.
145. Miller LM, Novatt JT, Hamerman D, Carlson CS. Alterations in mineral composition observed in osteoarthritic joints of cynomolgus monkeys. *Bone.* 2004;35(2):498-506.
146. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. *N Engl J Med.* 2004;350(20):2033-41.
147. Raisz LG. Homocysteine and osteoporotic fractures-culprit or bystander? *N Engl J Med.* 2004;350(20):2089-90.
148. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP. Homocysteine as a predictive factor for hip fracture in older persons. *N Engl J Med.* 2004;350(20):2042-9.
149. Fratzl P, Fratzl-Zelman N, Klaushofer K. Collagen packing and mineralization. An x-ray scattering investigation of turkey leg tendon. *Biophys J.* 1993;64(1):260-6.
150. Fratzl P, Fratzl-Zelman N, Klaushofer K, Vogl G, Koller K. Nucleation and growth of mineral crystals in bone studied by small-angle X-ray scattering. *Calcif Tissue Int.* 1991;48(6):477-15.
151. Kulkarni A, Wyrobek J, Qian Z, Silverstein J, Judy J. Comparison of nanomechanical properties of amorphous carbon and carbon-nitrogen thin coatings. In: Kumar A, Chung Y, Chia R (eds.) *The Minerals, Metals, and Materials Society*, 1998.
152. Oliver W, Pharr G. An improved technique for determining hardness and elastic modulus using load and displacement sensing indentation experiments. *J Mater Res.* 1992;7:1564-1583.